Biogen drug slows progress of motor neurone disease in landmark trial
Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis
Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis